Have any questions? 706-721-6582 or cts@augusta.edu
- A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 3 Dose Levels of NMD670 over 21 Days in Adult Patients with AChR/MuSK-Ab+ Myasthenia Gravis
Clinical Trial
A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 3 Dose Levels of NMD670 over 21 Days in Adult Patients with AChR/MuSK-Ab+ Myasthenia Gravis
An experimental drug called NMD670 has been shown to help patients with myasthenia gravis (MG) by improving their muscle weakness and fatigue.The main goal of this study is to learn the how well different doses of this experimental drug works and how safe these doses are. The participants should have a diagnosis of occular or generalized MG and have and are positive for AChR or MuSK antibodies.
Eligibility Criteria
- Inclusion Criteria: You are diagnosed with Occular or gMG and have a documented positive AChR or MuSK antibody test. You have a QMG total score of 11 or more and MG-ADL score of 6 or more at screening Exclusion Criteria: You had a thymectomy within 6 months of screening or plan to have one during the study You have a history of thymic cancer unless deemed cured by treatment with no evidence of reoccurrence for more than 5 years You are unable to undergo ophthalmologic (eye) evaluation at screening. You have used rituximab 6 months prior to screening.
RESEARCH. INNOVATION. DISCOVERY.